$216 Million is the total value of Prosight Management, LP's 42 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 54.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $11,194,000 | -8.2% | 145,700 | -10.6% | 5.17% | -10.8% |
| BMY | Sell | BRISTOL-MYERS SQUIBB CO | $10,483,000 | -6.3% | 169,000 | -8.9% | 4.84% | -8.9% |
| BAX | Sell | BAXTER INTL INC | $9,715,000 | -1.0% | 121,075 | -0.8% | 4.49% | -3.8% |
| CI | Sell | CIGNA CORP NEW | $8,622,000 | +8.3% | 41,418 | -11.9% | 3.98% | +5.2% |
| CHNG | Sell | CHANGE HEALTHCARE INC | $7,843,000 | -13.4% | 420,514 | -32.6% | 3.62% | -15.9% |
| AUPH | Sell | AURINIA PHARMACEUTICALS INC | $7,036,000 | -19.7% | 508,715 | -14.5% | 3.25% | -22.0% |
| ALDX | Sell | ALDEYRA THERAPEUTICS INC | $6,232,000 | -23.0% | 908,488 | -16.8% | 2.88% | -25.2% |
| MGTX | Sell | MEIRAGTX HLDGS PLC | $5,770,000 | +11.4% | 381,119 | -2.6% | 2.67% | +8.2% |
| ZBH | Sell | ZIMMER BIOMET HOLDINGS INC | $5,470,000 | -17.3% | 35,501 | -27.0% | 2.53% | -19.7% |
| Sell | APTOSE BIOSCIENCES INC | $3,613,000 | -47.1% | 824,795 | -27.6% | 1.67% | -48.7% | |
| ZGNX | Sell | ZOGENIX INC | $2,989,000 | -7.8% | 149,522 | -17.4% | 1.38% | -10.4% |
| CNC | Sell | CENTENE CORP DEL | $2,401,000 | -65.1% | 40,000 | -66.1% | 1.11% | -66.1% |
| QURE | Sell | UNIQURE NV | $1,947,000 | -69.2% | 53,900 | -68.6% | 0.90% | -70.0% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $1,497,000 | -86.6% | 12,112 | -89.4% | 0.69% | -87.0% |
| IMTX | Sell | IMMATICS N.V | $1,133,000 | -5.9% | 104,999 | -7.5% | 0.52% | -8.7% |
| MGTA | Sell | MAGENTA THERAPEUTICS INC | $985,000 | -40.7% | 125,654 | -48.6% | 0.46% | -42.4% |
| ACIU | Sell | AC IMMUNE SA | $46,000 | -99.0% | 8,942 | -99.0% | 0.02% | -99.0% |
| Exit | REATA PHARMACEUTICALS INCcall | $0 | – | -1,600 | -100.0% | -0.07% | – | |
| BEAT | Exit | BIOTELEMETRY INC | $0 | – | -6,000 | -100.0% | -0.13% | – |
| MITO | Exit | STEALTH BIOTHERAPEUTICS CORPsponsored ads | $0 | – | -256,044 | -100.0% | -0.16% | – |
| KIDS | Exit | ORTHOPEDIATRICS CORP | $0 | – | -8,399 | -100.0% | -0.18% | – |
| APEN | Exit | APOLLO ENDOSURGERY INC | $0 | – | -277,590 | -100.0% | -0.22% | – |
| EVFM | Exit | EVOFEM BIOSCIENCES INC | $0 | – | -250,000 | -100.0% | -0.28% | – |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -66,376 | -100.0% | -0.38% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -15,826 | -100.0% | -0.58% | – |
| BTAI | Exit | BIOXCEL THERAPEUTICS INC | $0 | – | -29,800 | -100.0% | -0.62% | – |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -301,678 | -100.0% | -0.62% | – |
| ESTA | Exit | ESTABLISHMENT LABS HLDGS INC | $0 | – | -86,042 | -100.0% | -0.76% | – |
| QDEL | Exit | QUIDEL CORP | $0 | – | -7,500 | -100.0% | -0.78% | – |
| KZR | Exit | KEZAR LIFE SCIENCES INC | $0 | – | -365,981 | -100.0% | -0.84% | – |
| ONEM | Exit | 1LIFE HEALTHCARE INC | $0 | – | -65,778 | -100.0% | -0.89% | – |
| AMRX | Exit | AMNEAL PHARMACEUTICALS INC | $0 | – | -512,659 | -100.0% | -0.95% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -107,367 | -100.0% | -1.56% | – |
| CLLS | Exit | CELLECTIS S Aspon ads | $0 | – | -185,180 | -100.0% | -1.63% | – |
| Exit | ISHARES TRput | $0 | – | -24,000 | -100.0% | -1.71% | – | |
| TBIO | Exit | TRANSLATE BIO INC | $0 | – | -282,100 | -100.0% | -1.83% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -120,606 | -100.0% | -1.89% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.